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A novel allergen-adjuvant conjugate suitable for specific
immunotherapy of respiratory allergy
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Francesca Nencini, MS,a Laura Maggi, PhD,a Sara Pratesi, MS,a Giulia Petroni, MS,a Francesca Boscaro, MS,c
Antonio Guarna, MS,b Ernesto G. Occhiato, MS,b Sergio Romagnani, MD,a Enrico Maggi, MD,a and
Paola Parronchi, MDa Florence, ItalyBackground: Several approaches to find a better adjuvant, focus
immunomodulation, and reduce allergenicity are under
investigation to improve the efficacy and safety of specific
immunotherapy.
Objective: We performed an investigation of the in vitro and
in vivo effects of a purified allergen chemically conjugated to a
novel 8-OH modified adenine as an adjuvant.
Methods: Purified group 2 major allergen from house dust mite
chemically conjugated to 4-(6-amino-9-benzyl-8-hydroxy-9H-
purin-2-ylsulfanyl)-butyric acid succinimidyl ester was analyzed
by using mass spectrometry. The adduct (nDer p 2–Conj) was
assayed for Toll-like receptor activation on transfected HEK293
cells, stimulation of innate cells, and effects on the functional
phenotype of specific T-cell lines and clones by means of flow
cytometry, real-time PCR, and expression of TH-related
transcription factors. Lung cells and sera of nDer p 2–Conj–
sensitized C57Bl/6 mice were studied by means of cytology,
histology, real-time PCR, and ELISA.
Results: nDer p 2–Conj stimulated IL-12 and IFN-a production
from monocytes and plasmacytoid dendritic cells, respectively,
retaining the ability to trigger Toll-like receptor 7 exclusively,
and expanded human allergen-specific lymphocytes with
reduced ability to produce TH2-related cytokines and increased
IFN-g levels, as based on GATA-3/T-bet expression. In vivo
adduct-sensitized mice exhibited reduced eosinophil infiltration
and IL-13 expression in the airways, IFN-g upregulation
together with IgE downregulation, and an increase in allergen-
specific IgG2a levels in sera. The conjugate exhibited reduced
ability to activate human FcεRI1 cells without inducing TH17
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84Conclusions: The codelivery of an allergen with a modified
adenine as a conjugate inducing modulatory cytokines from
innate cells redirects in vitro and in vivo pathogenic TH2
responses without eliciting harmful effects. (J Allergy Clin
Immunol 2013;132:84-92.)
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Allergic diseases are triggered by allergen-specific CD41 TH2
responses inducing IgE antibody levels and accumulation of eo-
sinophils and other cell types at the sites of allergen penetration
and inflammation.1 Although steroids, antihistamines, and
immunosuppressors usually control allergic diseases, specific
immunotherapy (SIT) is the only treatment able to modify the
pathogenic mechanisms.2 However, currently available SIT can-
not be used in patients with allergic diseases characterized by
more severe symptoms (uncontrolled/severe bronchial asthma,
atopic dermatitis, and food allergy) in whom interference with
allergen-specific TH2 responses would be highly desirable.
Thus different approaches are under investigation to ameliorate
this procedure, including optimization of antigens, new adminis-
tration routes, and novel adjuvants.3-5 Traditionally, subcutaneous
SIT uses aluminum hydroxide, contributing to the formation of
antigen depot at the inoculation site. In the mouse alum has
been associated with the induction of TH2 responses to coformu-
lated antigens, even if its effects in human subjects are less clear.6
Recently, several low-molecular-weight synthetic compounds
able to bind Toll-like receptors (TLRs) on dendritic cells (DCs)
have been suggested as possible alternative adjuvants in therapeu-
tic vaccines.4,7 For example, the dispersible TLR4 agonist mono-
phosphoryl lipid A (MPL-A), which is licensed for effective
protection against papilloma and hepatitis B viruses,8 when incor-
porated in pollen-specific subcutaneous immunotherapy, resulted
in allergen-specific TH2 suppression in favor of IL-12–mediated,
monocyte-dependent protective TH1 responses. Furthermore, the
administration of an MPL-adjuvanted grass pollen vaccine
through the sublingual route (sublingual immunotherapy) seems
to be safe and associated with suppression of nasal challenge.9
Actually, the chemical conjugation between allergens and
adjuvants can further improve vaccine constructs by providing
the delivery of the 2 components inside the same antigen-
presenting cell (APC) with a more focused innate activation
and better interferencewith immunopathogenicmechanisms. The
chemical linkage between antigens and TLR ligands eventually
ensures safety, inducing protective IgG isotype antibody without
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and reduced allergenicity were observed in vitrowith the purified
allergen Amb a 1 linked to a 22-mer oligodeoxynucleotide
sequence binding TLR9.10 The administration of theAmb a 1–oli-
godeoxynucleotide conjugate in atopic patients was associated
with significant improvements in nasal symptoms, downregula-
tion of IgE, a transient increase in specific IgG levels, and locally
reduced numbers of eosinophils and IL-4–producing cells.11-13
Regarding TLR7/8 agonists, 3M012, which belongs to the imida-
zoquinoline family, conjugated to the HIV Gag protein after UV
exposure enhanced the magnitude of the immune response in
the mouse.14 By using the same conjugation procedure, it was
also observed that vaccination with an ovalbumin/3M042–cou-
pled compound resulted in an IL-12p40– and type I interferon–
dependent strong CD41 and CD81 TH1 immunity, promoting
antigen uptake by several resident and migratory DC subsets.15
We have previously shown that the mixture of an antigen (or a
hapten) with 2,9-substituted 8-hydroxy adenines deeply influ-
enced the phenotype of antigen-specific effectors both in human
subjects and mice.16,17 Taking advantage of a coupling technique
using mild nondenaturing conditions and untouched proteins, we
show here that a conjugated compound between 4-(6-amino-9-
benzyl-8-hydroxy-9H-purin-2-ylsulfanyl)-butyric acid succini-
midyl ester (an 8-OHmodified adenine; SA-26E) and the purified
natural Dermatophagoides pteronyssinus group 2 allergen from
house dust mite (HDM) is able to redirect allergen-specific TH2
responses in human subjects in vitro and to promote a TH1 profile
in a murine model of allergic sensitization in vivo through TLR7
triggering without harmful effects, such as induction of
autoantibodies or overt autoimmunity.
METHODS
Preparation of the conjugate
Synthesis of SA-26E and conjugation and characterization of synthetic
products are described in the Methods section and Fig E1 in this article’s
Online Repository at www.jacionline.org.
Donors
PBMCs from 10 healthy volunteers and 14 adult atopic donors
sensitized to Dermatophagoides pteronyssinus (as documented by history,skin test results, and serum IgE levels measured with the CAP-FEIA;
Thermo Fisher/Phadia, Uppsala, Sweden) were obtained in accordance
with the ethical standards of the responsible regional Committee on human
experimentation.
Reporter assay of TLR-expressing HEK293 cells
Nuclear factorkB (NF-kB) reporter assay of stably expressing humanTLR7,
human TLR8, or mouse TLR7 HEK293 cells was performed, as previously
described16 and specified in the Methods section in this article’s Online
Repository.
Production of cytokines by innate immune cells
IL-12p40, IFN-a, TNF-a (Invitrogen, Carlsbad, Calif), IL-10 (BD
PharMingen, San Jose, Calif), and IL-6 (R&D Systems, Minneapolis, Minn)
were quantified by means of ELISA in purified CD141 and BDCA-41 cell
supernatants of 10 healthy volunteers, as described in the Methods section
in this article’s Online Repository.
Generation of antigen-specific short-term T-cell
lines and T-cell clones and functional analysis
Allergen-specific T-cell lines (TCLs) from PBMCs of 10 atopic donors and
CD41CRTH21 T cells of 4 atopic donors were generated in the presence of
nDer p 2 or nDer p 2–Conj (10 mg/mL), as previously described18 and speci-
fied in the Methods section in this article’s Online Repository.
Allergen-specific T-cell clones (TCCs) from 2 allergic donors were
obtained, as previously reported.16,18
The functional phenotype of T-cell blasts was analyzed as described in the
Methods section in this article’s Online Repository.
Cytofluorimetric evaluation of basophil activation
Basophil activation was evaluated in heparinized whole blood from 4
HDM-sensitive patients challenged with serial dilutions of nDer p 2 or nDer
p 2–Conj using a commercial kit (Becton Dickinson, Franklin Lakes, NJ), as
reported in the Methods section in this article’s Online Repository.
Animals
Female C57Bl/6 mice (Charles River, Burlington, Mass) were housed
under specific pathogen-free conditions and aged between 6 and 8weeks at the
start of the experiments. Experiments were approved by the institutional
national guidelines and followed local animal ethics regulations.Induction of experimental allergic sensitization
Mice were intraperitoneally sensitized at days 0 and 7 with 100 mL of PBS
containing either nDer p 2 or nDer p 2–Conj (10mg) or the mixture of nDer p 2
(10 mg) and free SA-26E (0.085 mg) adsorbed onto 2.25 mg of alum (Imject;
Pierce, Rockford, Ill). Negative control animals were sham sensitized with
PBS in alum. Mice were intratracheally challenged at day 14 and day 18 by
means of administration of nDer p 2 (10 mg in 50 mL of PBS) and killed by
means of intraperitoneal injection of pentobarbitone 72 hours after the last
nDer p 2 exposure (day 21).Analysis of BALF and lung specimens
Bronchoalveolar lavagewas performed, as previously described.19 BALF cells
weremorphologically characterizedwithDiff-Quick and analyzed on a FACSCa-
libur flow cytometer (Becton Dickinson) by using CellQuest software after stain-
ing with fluorescein isothiocyanate–labeled anti-CD3, allophycocyanin-labeled
anti-CD8, and phycoerythrin-labeled anti-CCR3 (Becton Dickinson).
Single-cell suspensions were obtained from lungs perfused with PBS/BSA
0.5%.17 Lungmononuclear cells were stimulated with nDer p 2 (50mg/mL) in
96-well round-bottom plates for 3 days, and IFN-g and IL-13 content was
measured in supernatants by using ELISA (R&D Systems).
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FIG 1. Preparation and characterization of nDer p 2–Conj. A, Covalent bond of SA-26E (left) to lysine resi-
dues of nDer p 2 (right). B, Conjugation ratios between SA-26E and nDer p 2 and percentages of unbound
allergen (P) and allergen linked to adenine fragments (P11, P12, P13, and P14). C, Mass spectrometric
analysis of nDer p 2–Conj.
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86 FILı ET ALPBS-perfused lungs were inflated with and fixed in 4% neutral buffered
formalin before paraffin embedding. Five-micrometer sections were prepared,
stained with Congo Red, counterstained with hematoxylin, and examined by
meansof lightmicroscopy toassess eosinophil infiltration. Imageswere obtained
with a Eurostar II microscope equipped with a 340 Zeiss N-ACHROPLAN
objective (total magnification 3400) and a PS 40-285 FW Kappa Optronics
digital camera. Eosinophils were counted in 10 random fields by an observer
blinded to the experimental conditions, and mean6 SE numbers were reported.
Immunoglobulin measurement and determination
of anti-nuclear autoantibodies
Total IgE and nDer p 2–specific IgG1 and IgG2a levels were quantified in
sera by using ELISA.17,19,20 Anti-nuclear autoantibodies (ANA) were
detected by means of indirect immunofluorescence at 1:20 serum as a starting
dilution by an observer blinded to the experimental conditions, as described in
the Methods section in this article’s Online Repository.Statistical analyses
Results are presented as means 6 SEs. Statistical analysis was performed
with the Student t test and Wilcoxon matched-pairs signed-rank test. P values
of less than .05 were considered significant.
RESULTS
Characterization of nDer p 2–Conj
SA-26E was conjugated to lysines of purified nDer p 2 through
an amidic bond (Fig 1,A) using different molar ratios (Fig 1,B) on
the basis of the molecular weight (14 kDa) and lysine content (14
residues) of nDer p 2. The coupling procedure was carried out
under nondenaturing conditions to maintain the intact protein
structure and avoid key epitope loss.
By using matrix-assisted laser desorption ionization–time-of-
flight (MALDI-TOF), conjugate 1 contained a portion of
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FIG 2. nDer p 2–Conj acts as a TLR7 ligand and activates innate immune cells. A, NF-kB–dependent lucifer-
ase activity of stimulated human TLR7 (hTLR7)–, human TLR8 (hTLR8)–, or mouse TRL7 (mTLR7)–express-
ing HEK293 cells (mean 6 SE, 5 experiments). B, Mean 6 SE cytokine concentrations in supernatants
of purified CD141 or BDCA-41 cells (10 healthy donors). ns, Not significant. *P < .05, **P < .005, and
***P < .0005.
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FILı ET AL 87unconjugated protein (14.097 kDa) and conjugates with molecular
weights of 14.439 and14.781kDa (protein linked to 1 or 2modified
adenine fragments of 341amu (atomicmass unit), respectively; Fig
1,B andC). By doubling amounts of allergen and active estermain-
taining a 0.74 molar ratio (moles of active ester/moles of lysines),
as in conjugate 2, identical spectra were obtained, indicating opti-
mal reproducibility. Increasingmolar ratio (3.2), as in conjugate 3,
unbound allergen reduced (22%), whereas protein-linked adenine
fragments increased (up to 4; Fig 1, B and C). nDer p 2–Conj
used throughout the study refers to conjugates obtained by using
the molar ratio of 0.74. The adduct was stable, and its activities
did not vary depending on the time of preparation (data not shown).
By using MALDI-TOF, the effective amount of protein-bound
adenine derivative was calculated at a molar ratio of 0.74
(0.085 mg for every 10 mg of conjugate). Thus 0.085 mg/mL
free SA-26Emixedwith 10mg/mL nDer p 2 was used as a control
in some experiments.nDer p 2–Conj is a TLR7 ligand and activates innate
immune cells
The induction of NF-kB expression in stably TLR-transfected
HEK293 cells was studied to assess whether the conjugation to a
protein affected the ability of SA-26E to trigger innate signaling.
Luciferase activity increased when nDer p 2–Conj was added to
human or murine TLR7-expressing HEK293 cells (Fig 2, A).
R-848 was active on TLR7- and TLR8-transfected cells, as previ-
ously reported.7 nDer p 2–Conj was devoid of any activity on
HEK293 cells expressing TLR3, TLR9, or TLR4. MyD882/2
cells were not activated by nDer p 2–Conj. nDer p 2 and nDer p
2 mixed to free SA-26E at the corresponding amounts present
in nDer p 2–Conj lacked any activity in the experimental models
(data not shown), whereas at higher concentrations, free SA-26E
was indeed able to trigger TLR7 exclusively (see Fig E2 in this
article’s Online Repository at www.jacionline.org).
We then investigated the ability of nDer p 2–Conj to induce
cytokine production by circulating human monocytes and
plasmacytoid dendritic cells (pDCs). nDer p 2–Conj elicited the
production of IL-12p40, TNF-a, and IL-6 in purified CD141 cellsfrom 10 healthy donors, whereas no difference in IL-10 produc-
tion was observed. nDer p 2–Conj also induced pDCs (purified
circulating BDCA-41 cells) derived from the same donors and
cultured under the same conditions as CD141 cells to produce
IFN-a, TNF-a, IL-6, and IL-10 (Fig 2, B). nDer p 2 did not stim-
ulate the production of any cytokine, likely because of its high
grade of purification and detoxification. Interestingly, the mixture
of nDer p 2 plus free SA-26E at amounts corresponding to those
present in nDer p 2–Conj was ineffective on both human mono-
cytes and pDCs. As expected, the TLR7/8 ligand R-848
(6 mmol/L), which was used as a positive control, induced the
maximal activation of both cell types (Fig 2, B).nDer p 2–Conj in vitro redirects human Der p 2–
specific TH2 cells to the TH1/TH0 profile
To address whether a modified adenine stably conjugated to a
protein allergen redirected the cytokine profile of specific T cells,
short-term TCLs from 10 HDM-sensitized atopic donors were
derived in response to nDer p 2 or nDer p 2–Conj, screened for
antigen specificity, and examined for cytokine production on
polyclonal stimulation. nDer p 2– or nDer p 2–Conj–induced
cultures proliferated equally well in response to the unbound
allergen (data not shown). A significant increase in the proportion
of IFN-g–expressing lymphocytes, paralleled by reduced propor-
tions of IL-4–expressing T cells, was found in nDer p 2–Conj–
derived TCLs in comparison with that seen in nDer p 2–derived
TCLs (Fig 3, A). Along with IL-4, nDer p 2–Conj–induced TCLs
also exhibited lower percentages of IL-13–expressing
(13.2% 6 7.0% vs 31.6% 6 7.2%, P < .005), IL-5–expressing
(6.3% 6 2.3% vs 17.5% 6 1.8%, P < .05), and IL-9–expressing
(0.8%6 0.3% vs 2.9%6 1.9%, P < .05) cells than unconjugated
nDer p 2–induced TCLs. No difference in the proportions of
IL-10– or IL-17–producing T cells was found. The mixture
between nDer p 2 and free SA-26E was inactive.
These results were confirmed by means of quantitative real-
time RT-PCR because nDer p 2–Conj–derived TCLs expressed
higher levels of IFN-g (and lower levels of IL-4, IL-5, and IL-13)
mRNA than nDer p 2–derived T-cell blasts (Fig 3, B). No
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FIG 3. nDer p 2–Conj redirects human allergen-specific TH2 cells to the TH1/TH0 profile. A, IL-4 and IFN-g in-
tracellular expression (mean 6 SE) by CD31CD41 T cells from polyclonally stimulated TCLs (10 donors).
B, Cytokine mRNA expression by TCLs (7 donors). Medians and 25th and 75th percentiles are shown in
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exhibiting the indicated phenotype (2 donors). D, GATA-3 and T-bet mRNA expression in TCLs (7 donors).
Medians and 25th and 75th percentiles are shown in boxes; minimum and maximum values are shown as
whiskers. E, IL-41, IFN-g1, or double-positive T-cell blasts of polyclonally stimulated CD41CRTH21 derived
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and anti–IFN-a mAbs (2 donors). *P < .05 and **P < .005. ns, Not significant.
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ability of nDer p 2–Conj to shift the functional phenotype of spe-
cific T cells was confirmed at the clonal level. Thirty-seven and 28
allergen-specific TCCs were obtained by limiting dilution from
nDer p 2–induced TCLs of 2 atopic donors, respectively, whereas
28 and 23 allergen-specific TCCs were derived from nDer p
2–Conj–derived cultures, respectively. No difference in clonal ef-
ficiency was found. High numbers of IL-4–producing clones and
clear-cut TH2 phenotype were derived from nDer p 2–induced
TCLs (24 clones). From nDer p 2–Conj–derived cultures, only4 of 51 clones still retained the ability to produce IL-4 alone,
whereas about one third of them produced IFN-g alone (14
clones; Fig 3, C).
At the transcriptional level, nDer p 2–Conj, in comparison with
unconjugated allergen-derived TCLs, expressed higher levels of
the TH1-related T-bet and lower levels of the TH2-related
transcription factor GATA-3 (Fig 3, D). No difference in TH17-
related RAR-related orphan receptor C or regulatory T cell–
related forkhead box protein 3 (Foxp3) was found. nDer p 2 plus
free SA-26E produced similar results to nDer p 2 (data not shown).
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FILı ET AL 89To demonstrate the functional redirection of already established
specific TH2 responses, TCLs were derived from circulating
CRTH21memory cells of 4HDM-sensitive donors in the presence
of nDer p 2or nDer p2–Conj.As expected, nDer p 2–inducedTCLs
exhibited high proportions of IL-4–expressing (and negligible
amounts of IFN-g–expressing) T lymphocytes. However, when
CRTH21 cells were cultured with nDer p 2–Conj, the expression
of IL-4 dramatically reduced and was associated with increased
production of IFN-g (alone or together with IL-4; Fig 3, E).Redirection activity of nDer p 2–Conj is dependent
on activation of innate immune cells
Because the addition of nDer p 2–Conj to purified T cells was
unable to modify their functional phenotype (data not shown), we
focused on the activity of innate cytokines on T-cell differenti-
ation. Thus TCLs were derived from 2 atopic donors with nDer p
2 or nDer p 2–Conj, the latter in the absence or presence of a
mixture of neutralizing anti–IL-12, anti–IFN-a, anti–IFN-a
receptor, and anti–IL-29 mAbs or IgG isotypes from nonimmu-
nized mice. The neutralization of IL-12 and IFN-a completely
restored the expression of IL-4 (reducing the production of
IFN-g) in nDer p 2–Conj–derived cultures (Fig 3, F). The neutral-
ization of IL-29 did not add any effect on TH1 switching (data not
shown).Stable conjugation of Der p 2 to adenine reduces
IgE-mediated allergen recognition by basophils
We next addressed whether the chemical conjugation dimin-
ished the ability to react to surface-bound IgE by analyzing
CD1231HLA-DR2 circulating basophils from 4HDM-sensitized
donors. CD63 expression was upregulated in response to either
anti-IgE antibody or nDer p 2. Vice versa, challenge with nDer
p 2–Conj was associated with progressive lower activation of
FcεRI1 cells in a dose-dependent manner (Fig 4).nDer p 2–Conj associates with reduced lung
inflammation and promotes IgG2a production in a
murine model of allergic sensitization
Four groups of mice were intraperitoneally sensitized twice
with nDer p 2, nDer p 2–Conj, nDer p 2 plus free SA-26E, or PBS
(all in alum) and challenged twice intratracheally with nDer p 2
(or PBS in the control group) to assess the in vivo effects of nDer p
2–Conj. Significantly reduced percentages of eosinophils werefound in the bronchoalveolar lavage fluid (BALF) of mice sensi-
tized with nDer p 2–Conj compared with those sensitized with
nDer p 2 or nDer p 2 plus free SA-26E. nDer p 2–Conj–sensitized
mice also exhibited restored macrophage counts with a limited
but significant increase in lymphocyte percentages (one third of
them represented by CD81 cells; Fig 5, A).
The evaluation of eosinophils in the perivascular, peribron-
chial, and alveolar districts showed that nDer p 2–Conj sensiti-
zation was followed by lower eosinophil infiltration than nDer p 2
or nDer p 2 plus free SA-26E sensitization (Fig 5, B and C). This
observation paralleled the increased expression of IFN-g and con-
comitantly reduced IL-13 expression at the mRNA and protein
levels in the lungs and in in vitro allergen-stimulated, lung-iso-
lated mononuclear cells of nDer p 2–Conj–primed mice com-
pared with nDer p 2– or nDer p 2 plus free SA-26E–primed
animals (Fig 5, D and E). At the serum level, total IgE amounts
were significantly lower in nDer p 2–Conj mice than in nDer p
2 or nDer p 2 plus free SA-26E mice and similar to levels seen
in control animals. Significantly increased Der p 2–specific
IgG2a levels were also seen in nDer p 2–Conj mice, whereas the
different sensitizations slightly affected allergen-specific IgG1
levels (Fig 5, F).nDer p 2–Conj does not induce autoimmune
responses in mice
Circulating ANAs were titered to assess the safety profile of
nDer p 2–Conj in terms of possible autoimmune responses. No
modification ofANA titerswas observed between nDer p 2–Conj–
primed and nDer p 2–primedmice. Similar frequencies of positive
ANA levels (see Table E1 in this article’s Online Repository at
www.jacionline.org), as well as autoantibodies exhibiting speck-
led nuclear patterns suggestive of Sm/RNP-specificity (anti-
RNA; data not shown), could be observed in the 3 groups of mice.DISCUSSION
The design of more powerful adjuvants is of crucial interest to
ameliorate vaccination strategies. Whereas there is a general
consensus about the optimal cytokine milieu for protective
immunization,21,22 immunologic mechanisms of successful SIT
are still controversial, with some authors favoring functional redi-
rection and others pointing to immune suppression.2,23-25 TLR
ligands, such as CpG oligodeoxynucleotides and MPL-A, have
been proposed as new adjuvants to drive and regulate adaptive
immune responses4 to improve SIT and overcome the issue of
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26,27 Recently,
we showed that the TLR7 ligand 9-benzyl-2-butoxy-8-
hydroxyadenine redirects pathogenic allergen-specific TH2 into
TH1 lymphocytes both in vitro and in vivo.
16,17 In this study we
reasoned that the chemical conjugation between an allergen and
a 8-OH modified adenine as an adjuvant, instead of a mixture
of the 2 components, might further improve the vaccine construct
by reducing systemic exposure, targeting appropriate APCs, and
inducing a more effective immunomodulation.
SA-26E was selected for its efficient chemical synthesis and
ability to spontaneously and easily couple the free amines of
proteins through a covalent bond under mild conditions. Further-
more, the backbone of SA-26E was suitable to attach proteins
maintaining the polar area (8-), the hydrophobic area (9-), and the
amino group (6-) essential for modulatory activities.28 Purified
detoxified nDer p 2 was chosen as a broadly recognized TH2-
inducing HDM allergen.29Modified 8-OH adenines are small polar molecules able to gain
the endosomal compartment,15 which might undergo alteration in
transmembrane permeability when conjugated. Actually, our ad-
duct still triggered human andmurine TLR7, with no activation of
other nucleic acid–recognizing receptors (TLR3, TLR8, or
TLR9) or cytosolic innate sensors differently from other immuno-
modulatory heterocycles.7 Consistently, the effect was lost when
MyD882/2 cells were used. These findings indicated that nDer p
2–Conj uniquely activated the MyD88- and NF-kB–dependent,
receptor 7 of the Toll-like family. The fact that the free active es-
ter, at the low levels as contained in the conjugate, was completely
inactive suggested that conjugation to the protein allowed to drive
of SA-26E directly to TLR7. As a possible alternative, a com-
pound partially different from SA-26E but still able to trigger
TLR7 might be released in the endosomal compartment after
protein digestion, resulting in the induction of cytokine release
by innate immune cells as well.
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cells instead of TH2 cells without any effect on Foxp3 expression
or IL-10 production. In this respect Foxp3 loss has been described
in DC–T-cell cocultures containing TLR7 ligands.30 The clonal
approach confirmed the true redirection activity of our conjugate
and also suggested that the coupling procedure did not affect
antigenicity because no difference in the numbers of allergen-
specific TCCs could be observed between nDer p 2– and nDer
p 2–Conj–derived cultures. Interestingly, in view of a targeted
therapeutic vaccine in which tuning of an already existing patho-
genic immunity is required, the TH1 polarization exerted by nDer
p 2–Conj principally or almost exclusively involved TH2-
establishedmemoryDer p 2–specific CRTH21 effectors T cells.31
Although T cells can express TLRs, including TLR7,32 the
shifting effect of nDer p 2–Conj was indirect and related to the
conditioned cytokine milieu produced by APCs because the neu-
tralization of IL-12 and IFN-a completely restored the ability of
Der p 2–specific T cells to produce high amounts of IL-4. IL-29,
expressed together with IFN-a by pDCs and macrophages in
response to TLR ligands, was irrelevant in this process, despite
its claimed role in TH2 regulation.
33
We then decided to investigate the possible in vivo effects of
nDer p 2–Conj in a murine prophylactic model of respiratory al-
lergy aimed to assess the possible pro-TH1 activity of the prepa-
ration. In nDer p 2–Conj–sensitized mice, IL-13 expression was
decreased in the lungs and in in vitro allergen-stimulated, lung-
isolated mononuclear cells, suggesting a prevalent effect on the
adaptive response. This decrease paralleled the reduction in eo-
sinophil numbers in BALF, inflammatory infiltration in lung
areas, and serum total IgE levels. The modest increase in T-lym-
phocyte numbers in BALF might be related to the generation of
CD81 responses and cross-priming induction, as described in
imidazoquinoline conjugates.34 Finally, although assessed in a
prophylactic model, the increased IFN-g expression paralleled
the in vitro results on human cells and the in vivo increase in
allergen-specific IgG2a antibody levels. Although the benefit of
TH redirection versus immunoregulation in SIT is still a matter
of debate,24,25 SIT is aimed at modifying the pathogenic TH2 ar-
rangement, restoring a physiologic TH profile. In this respect it ap-
pears favorable to gain IFN-g as playing a pivotal role against
allergy risk and asthma development. Furthermore, both transma-
ternal allergoprotection and prevention of airway allergic inflam-
mation have been recently demonstrated as depending on the
epigenetic control of the IFNG promoter but not on modifications
of IL-10 levels.35,36
Several undesirable effects have been related to the triggering of
TLRs. Innate receptor signaling has been associated with lung
inflammation andTH17 response related to disease severity in asth-
matic patients.37 nDer p 2–Conj did not promote the development
of harmful TH17 cells, which is in agreement with our observation
that modified adenine 9-benzyl-2-butoxy-8-hydroxyadenine in-
hibits the production of IL-17A and IL-17–related molecules in
mice.20 Hypoallergenic derivatives with reduced ability to bind
IgE and activate FcεRI1 cells but preserving T-cell epitopes have
been proposed to improve the safety of allergy vaccines.5 Notably,
nDer p 2–Conj is associated with a lower activation of basophils,
whereas the frequency of allergen-specific T cells did not vary.
Its reduced IgE reactivitymight reside in conformationalmutation,
reduced accessibility, or both of the allergen molecule because of
SA-26E attached to outward-facing lysine residues. Finally, al-
though the stimulation of the TLR7/8 pathway has been variablyassociated with autoimmunity,38,39 anti-nuclear antibodies levels
were low, with no difference in titers, frequency of positivity, or
both in the different groups of mice. Serum ANA levels were per-
manently low even 6months after nDer p 2–Conj or nDer p 2 prim-
ing (Vultaggio et al, manuscript in preparation). Although clinical
datawouldbe required to effectively demonstrate the safety profile,
these in vitro and in vivo findings suggest that our conjugate might
represent a useful tool in allergy vaccines.
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Clinical implications: Stable conjugation of allergen or aller-
gens to the novel adjuvant 8-OH modified adenines might rep-
resent a useful, reproducible, plastic tool to improve SIT for
the treatment of allergic diseases.REFERENCES
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General procedures for purification and
characterization of synthetic products
Chromatographic separations were performed under pressure on silica gel
60 (70-230 mesh; Merck, Whitehouse Station, NJ) using flash-column
techniques; Rf (ratio frontis) values referred to TLC (Thin Layer Chromatog-
raphy) carried out on 0.25-mm silica gel plates with the same eluant indi-
cated for the column chromatography. Commercial anhydrous DMF
(Dimethyl formamide) was used. 1H nuclear magnetic resonance (NMR;
400 and 200 MHz) and 13C NMR (50.33 and 100.4 MHz) spectra were
recorded at 258C. Mass spectra were determined by using a direct inlet on
an LCQ Fleet Ion Trap LC/MS system (Thermo Fisher Scientific) with an
electrospray ionization (ESI) interface in the positive mode. Compound III
is known.E1,E2
Synthesis of SA-26E
Synthesis of the active ester SA-26E (Fig E1) was realized, starting from
the modified adenine 6-amino-9-benzyl-2-mercapto-9H-purin-8-ol III pre-
pared, as previously reported.E1,E2 Adenine derivative (III) was initially func-
tionalized with a linker bymeans of treatment with ethyl 4-bromobutanoate (1
equivalent) in anhydrous DMF and in the presence of K2CO3 as a base to pro-
vide ester (IVa) in 54% yield after chromatography. Ethyl ester (IVa) was then
hydrolyzed in alkaline medium with KOH in a 3:1 methanol/water mixture.
After 48 hours, the methanol was evaporated, and the pH of the resulting
solution was adjusted to pH 3 with 10% NaHSO4, thus leading to the precip-
itation of acid (Va; 70% yield). The active ester SA-26E was finally obtained
by dissolving the acid Va in anhydrous DMF and adding dicyclohexylcarbo-
diimide in a slight excess, followed by N-hydroxysuccinimide, according to
standard conditions. After chromatography of the crude reaction mixture,
the active ester SA-26E was obtained in a 79% yield.
4-(6-Amino-9-benzyl-8-hydroxy-9H-purin-2-
ylsulfanyl)-butyric acid ethyl ester (IVa)
In a 100-mL 2-necked flask, compound III (1.4 g, 5.12 mmol) was
dissolved in 40 mL of anhydrous DMF in a nitrogen atmosphere. Molecular
sieves (4 A) were added to remove possible traces of water present in the
substrate, and the solution was stirred at 258C for 35minutes. K2CO3 (0.708 g,
5.12 mmol) was then added, and the solution was stirred for 1 hour. Ethyl
4-bromobutanoate (0.703 mL, 5.12 mmol) was then added, and the reaction
was stirred at room temperature for 20 hours. The solvent was then removed
by means of distillation under vacuum heating at 368C, and sterile water
(5 mL) was added to the residue. Ayellow precipitate formed, and the suspen-
sion was brought to pH 7 by using a 10%KHSO4 solution in sterile water. The
formed precipitated was filtered, thus obtaining a yellow solid (1.6 g), which
was purified by means of chromatography on silica gel (eluant CH2Cl2/
MeOH, 40:1, Rf 0.16), obtaining 1.073 g (2.77 mmol) of compound IVa as a
pale yellow powder (54% yield).
1H NMR (400 MHz, dimethyl sulfoxide [DMSO], 258C) d: 1.17 (t, J5 7.0
Hz, 3 H), 1.84-1.91 (m, 2 H), 2.38 (t, J5 7.4 Hz, 2 H), 3.07 (t, J5 7.3 Hz, 2 H),
4.04 (q, J5 7.0Hz, 2 H), 4.89 (s, 2 H), 6.63 (br s, 2 H), 7.24-7.32 (m, 5H), 10.3
(br s, 1 H).
13C NMR (100.4MHz, DMSO, 258C) d: 15.0 (q), 25.8 (t), 30.3 (t), 32.5 (t),
43.4 (t), 60.7 (t), 101.3 (s), 128.3 (d), 128.5 (d, 2 C), 129.4 (d, 2 C), 138.1 (s),
147.9 (s), 148.9 (s), 152.7 (s), 162.0 (s), 173.3 (s). MS (ESI-MS) m/z (%):
C18H21N5O3S, 388 (M
1 1 1, 24), 342 (100). Mp 5 123-1278C.
4-(6-Amino-9-benzyl-8-hydroxy-9H-purin-2-
ylsulfanyl)-butyric acid (Va)
In a 50-mL flask compound IVa (0.421 g, 1.09 mmol) was partially
dissolved in 23mL of a 3:1 mixture ofMeOH and sterilewater. KOH (0.184 g,
3.77 mmol) was then added, resulting in the complete solubilization of the
starting material. The reaction was stirred at 258C for 48 hours, and after that
time, the solution appeared clear and dark yellow. After removing the MeOH
under vacuum, the residual aqueous solution was acidified to pH 3 with a 10%
solution of NaHSO4 in sterile water, thus obtaining a pale yellow precipitate.This was filtered and washed with a slightly acid aqueous solution, then with
water, and finally with dichloromethane. The product was finally dried under a
vacuum, thus obtaining 274 mg (0.76 mmol) of product Va (70% yield).
1H NMR (400 MHz, DMSO, 258C) d: 1.85-1.92 (m, 2 H), 2.36 (t, J 5 7.4
Hz, 2 H), 3.08 (t, J5 6.6 Hz, 2 H), 4.92 (s, 2 H), 6.54 (br s, 2 H), 7.28-7.36 (m,
5 H), 10.1 (br s, 1 H), 12.1 (br s, 1 H).
13C NMR (100.4 MHz, DMSO, 258C) d: 25.7 (t), 30.4 (t), 33.6 (t), 43.5 (t),
101.3 (s), 128.4 (d), 128.6 (d, 2 C), 129.4 (d, 2 C), 138.0 (s), 147.8 (s), 148.9
(s), 152.7 (s), 162.1 (s), 174.9 (s).
MS (ESI-MS) m/z (%): C16H17N5O3S 360 (M
1 1 1, 6), 342 (100), 274
(17). Mp 5 2308C (dec).
4-(6-Amino-9-benzyl-8-hydroxy-9H-purin-2-
ylsulfanyl)-butyric acid 2,5-dioxo-pyrrolidin-1-yl
ester (SA-26E)
In a 2-necked flask, the acid Va (0.249 g, 0.69 mmol) was dissolved in 5.5
mL of anhydrous DMF during stirring and in a nitrogen atmosphere in the
presence of molecular sieves (4A). Dicyclohexylcarbodiimide (157 mg, 0.76
mmol) was added, followed byN-hydroxysuccinimide (80mg, 0.69mol). The
resulting solution was stirred at room temperature for 23 hours, after which
time the solution appeared cloudy. The solution was filtered, and the solvent
was removed under a high vacuum by heating at 338C. The residue (490
mg) was purified by means of chromatography on silica gel (eluant CH2Cl2/
MeOH, 40:1, Rf 0.11) to produce 247 mg (0.54 mmol) of SA-26E as a bright
yellow powder (78%).
1H (DMSO, 258C) d: 1.94-2.01 (m, 2 H), 2.77 (t, J5 7.4 Hz, 2 H), 2.80 (s, 4
H), 3.10 (t, J 5 6.6 Hz, 2 H), 4.88 (s, 2 H), 6.53 (s, 2 H), 7.24-7.34 (m, 5 H),
10.1 (s, 1 H).
13C NMR (100.4MHz, DMSO, 258C) d: 24.4 (t), 25.4 (t, 2 C), 29.3 (t), 33.3
(t), 42.5 (t), 100.4 (s), 127.4 (d), 127.6 (d, 2 C), 128.5 (d, 2 C), 137.0 (s), 146.9
(s), 148.0 (s), 151.8 (s), 160.8 (s), 170.2 (s).
MS (ESI-MS) m/z (%): C20H20N6O5S, 457 (M
1 1 1, 6), 342 (100).
Mp 5 1618C (dec).
General procedure for the preparation of the
conjugate between active ester SA-26E and nDer p 2
In a glass vial the allergen nDer p 2 was dissolved in 0.5 mL of a 0.1 mol/L
phosphate buffer at pH 7.4. The active ester SA-26E, which was dissolved in
DMSO (130 mL), was diluted to 1 mL with the same phosphate buffer and
transferred into the vial containing the allergen (for a final volume of 1.5 mL).
The solution was stirred mechanically at 48C for 18 hours and then dialyzed
extensively against sterile PBS with a 2,000 Da molecular weight cutoff slide-
A-lyzer cassettes (Pierce). nDer p 2–Conj was placed in aliquots and stored at
2208C until use.
Mass spectrometry
Protein solutions at an approximate 0.5 to 1.0 mg/mL concentration were
desalted/concentrated with a C4 ZipTip (Millipore, Temecula, Calif), accord-
ing to the instructions of the producer, beforemass spectrometric experiments.
MALDI-TOF mass spectra were acquired with an Ultraflex III MALDI-TOF/
TOF (Bruker Daltonics, Bremen, Germany)mass spectrometer. Sinapinic acid
(20 mg/mL in 70:30 acetonitrile/water containing 0.1% trifluoroacetic acid)
was used as thematrix: this solutionwasmixed to desalted protein solution in a
1:1 volume ratio. A 1- to 2-mL volume was deposed on the MALDI target and
left to dry. Mass spectra were acquired in linear mode in the mass range of
3,000 to 20,000 m/z; 500 to 1,000 laser shots were summed. Ultraflex III
parameterswere as follows: IS (ion source) 1, 25 kV; IS 2, 23.45 kV; and 100 ns
delay time. FlexAnalysis (3.0 version) was used for data analysis.
Reagents
The LoTox natural purified group 2 major allergen of Dermatophagoides
pteronyssinus (nDer p 2) used throughout the study was purchased from
INDOORBiotechnologies (Charlottesville, Va; batch no. 31059) and certified
to contain less than 0.03 EU/mg protein. On the basis of the manufacturer’s
purification protocol, nDer p 2 contains the isoallergens 0101, 0102, and 0103.
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Berlin, Germany) was supplemented with low-endotoxin 2 mmol/L L-gluta-
mine, 1% nonessential amino acids, 1% sodium pyruvate, and 2 3 1025
mol/L 2-mercaptoethanol (all from Sigma Chemical Co, St Louis, Mo; com-
plete medium). FCS was from HyClone (Thermo Scientific). Phorbol
12-myristate 13-acetate (PMA), ionomycin, and brefeldin A were purchased
from Sigma-Aldrich. PHA was purchased from Gibco (Carlsbad, Calif).
R-848 (resiquimod, S28463) was from InvivoGen (San Diego, Calif). rIL-2
was from Novartis (Proleukin; Novartis, Basel, Switzerland). The endotoxin
content of all the reagents used throughout the study was assessed by using
the LAL test (BioWhittaker, Lonza).
Reporter assay of TLR-expressing HEK293 cells
HEK293 cells stably expressing human TLR7, human TLR8, or mouse
TRL7 (InvivoGen) were transiently transfected by means of nucleofection
(Amaxa GmbH, Cologne, Germany) with 2 mg of the ELAM-1 promoter NF-
kB luciferase reporter plasmid (pNifty, InvivoGen) purified with EndoFree
PlasmidMaxi kit (Qiagen, Hilden, Germany).E3 pmaxGFP (Amaxa) was used
as transfection efficiency control. After transfection, 1 3 105/mL cells were
plated in 48 flat-bottomed plates in Dulbeccomodified Eaglemedium (Sigma)
supplemented with 2 mmol/L L-glutamine and 5% FCS for 18 hours and then
stimulated with R848 (6 mmol/L), nDer p 2, or nDer p 2–Conj (10 mg/mL) or
medium alone as a negative control for a further 18 hours. At the end of the
culture, luciferase activity was determined in cell lysates by using a luciferase
Assay System (Promega, Madison, Wis).
HEK-Blue hNOD1 and 2 and Ramos-blue defMyD cells (InvivoGen) were
used according to the manufacturer’s instructions.
Production of cytokines by purified CD141 and
BDCA-41 cells
PBMCs from buffy coats of 10 healthy volunteers were isolated by means
of Ficoll-Hypaque, and magnetic cell sorting–selected CD141 cells (CD14
isolation kit; Miltenyi Biotec, Bergisch Gladbach, Germany) and BDCA-41
pDCs (BDCA-4 isolation kit, Miltenyi Biotec) were seeded at 1 3 106/mL
in 48-well flat-bottomed plates in complete medium plus 10% heat-
inactivated FCS (HyClone, Logan, Utah) in the absence or presence of nDer
p 2 or nDer p 2–Conj (both 10 mg/mL). R-848 (6 mmol/L) was used as a pos-
itive control. Purity of the cell populationswas assessed by using fluorescence-
activated cell sorting analysis and was always greater than 98%. After 36
hours’ incubation, supernatants from CD141 and BDCA-41 cells were col-
lected, centrifuged, and stored at 2208C.
Amounts of IL-12p40, IFN-a, TNF-a (Invitrogen), IL-10 (BD PharMin-
gen), and IL-6 (R&D Systems) were evaluated by using specific commercial
ELISAs, according to the manufacturer’s instructions.
Generation of allergen-specific short-term TCLs and
TCCs
Allergen-specific short-term TCLs were generated, as previously descri-
bed.E4 Briefly, PBMCs from 10 HDM-sensitive donors were obtained by
means of centrifugation on Ficoll-Hypaque gradient and stimulated with
nDer p 2 or nDer p 2–Conj (both at 10 mg/mL) for 6 days in complete medium
containing 5% autologous serum. On day 6, activated T cells were expanded
for the subsequent 8 days by the addition of rIL-2 (20 U/mL).
To generate short-term TCLs from purified CRTH21 T cells, PBMCs from
4 HDM-sensitive patients were obtained by means of centrifugation on Ficoll-
Hypaque gradient, and positively magnetic cell sorting–selected
CD41CRTH21 T cells (purity >98%) were stimulated in complete medium
plus 5% autologous serum in the presence of nDer p 2 or nDer p 2–Conj
(both at 10 mg/mL) and autologous highly purified CD141 cells. After 6
days of culture, activated T cells were expanded in the presence of rIL-2
(20 U/mL), and on day 14, T-cell blasts were collected for functional analysis,
as described below.
The specificity of short-term TCLs and TCCs was assessed, as previously
described.E3,E4 Briefly, 5 3 104 T-cell blasts were incubated in the presence
of 5 3 104 autologous irradiated PBMCs as APCs in the absence orpresence of allergen (nDer p 2, 10 mg/mL) for 48 hours in a 0.2-mL final
volume in duplicate. After a 16-hour pulse with 0.5 mCi 3HTdR (Perki-
nElmer, Waltham, Mass), cultures were harvested (TomTec, Boulder,
Colo) and radionuclide uptake was measured by using scintillation counting
(Wallac, Turku, Finland). TCLs and TCCs were considered specific when
the mitogenic index was 3 or greater.
T-cell blasts from allergen-specific short-term TCLs obtained from 2
allergic donors were cloned under limiting dilution (0.3 cells per well), as
previously reported.E3,E4
In the inhibition experiments neutralizing anti–IL-12 (R&D Systems),
anti–IFN-a (Biosource, Camarillo, Calif), anti–IFN-a receptor, and anti–IL-
29 (R&D Systems) mAbs were added at the beginning of the culture at a
concentration of 10 mg/mL. In parallel cultures control isotype mAbs were
used (R&D Systems).
Flow cytometric analysis of surface molecules
To evaluate the percentages of the different populations of cells in allergen-
specific TCLs, 23 105 cells were collected at the time of cytokine assessment,
resuspended in PBS containing BSA 0.5% and 0.02% sodium azide, and, after
saturation of nonspecific binding sites with total rabbit IgG, incubated for 20
minutes with specific (anti-CD3, anti–T-cell receptor [TCR] ab, anti-TCRgd,
anti-CD4, anti-CD8, anti-CD16, anti-CD20, and anti-CD56) or isotype con-
trol mAbs (Becton Dickinson). The cells were then washed and analyzed
with a FACSCalibur cytofluorimeter (Becton Dickinson), acquiring a total
of 104 cells for each sample.
Intracytofluorimetric analysis of cytokine
production
Intracytofluorimetric analysis of IL-4, IFN-g, IL-5, IL-9, IL-10, IL-13
(Becton Dickinson), and IL-17 (eBioscience, San Diego, Calif) synthesis at
the single-cell level after polyclonal stimulation with PMA (10 ng/mL) and
ionomycin (1 mmol/L) was performed, as previously described.E3,E4 Cells
were analyzed on a FACSCalibur cytofluorimeter with CellQuest software
(Becton Dickinson). The area of positivity was determined by using an
isotype-matched mAb. In all cytofluorimetric analyses, a total of 104 events,
gated as CD31CD41TCRab1 cells for each sample, were acquired.
Measurement of cytokines in the supernatants of
allergen-specific TCLs and TCCs
The ability of allergen-specific TCLs and TCCs to produce cytokines was
evaluated after polyclonal stimulation of 106/mL viable T-cell blasts with
20 ng/mL PMA plus 50 ng/mL anti-CD3 mAb (UCHT1, Becton Dickinson) in
a 1-mL volume for 36 hours. Amounts of IL-4, IL-5, IL-10 (Becton Dickinson),
IL-17, IL-13 (R&D Systems), and IFN-g (Endogen) were measured in cell-free
supernatants by using homemade ELISAs with commercial pairs of mAbs.
RNA extraction and quantitative real-time RT-PCR
Total RNAwas extracted frommouse lung cells and human TCLs by using
the RNeasy Kit (Qiagen) and treated with DNase I (Qiagen) to eliminate
possible genomic DNA contamination and quantified with the NanoDrop
spectrophotometer (Thermo Scientific).
cDNA from each sample was synthesized from 1 mg of total RNA with
TaqMan Reverse Transcription Reagents (Applied Biosystems, Foster City,
Calif), according to the manufacturer’s protocol. Real-time PCR was
performedwith anABI PRISM7900HT SequenceDetection System (Applied
Biosystems), according to the manufacturer’s instructions. All PCR amplifi-
cations were performed on the MicroAmp optical 96-well reaction plate with
TaqMan Universal Master Mix and Assay on Demand (Applied Biosystems).
Each assaywas carried out in duplicate and included a no-template sample as a
negative control. Relative expression of mRNA levels was determined by
comparing experimental levels with a standard curve generated with serial
dilution of cDNA obtained from human PBMCs. b-Actin and ubiquitin were
used as housekeeping genes for normalization of human and mouse experi-
ments, respectively.
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A basophil activation kit (Becton Dickinson) was used, according to the
manufacturer’s recommendations. Aliquots (100 mL) of heparinized whole
blood from 4 HDM-sensitive patients were incubated with 20 mL of
stimulation buffer (negative control) for 15 minutes at 378C in a water bath
or with 20mL of serial dilutions of nDer p 2 or nDer p 2–Conj (0.5-0.05-0.005
mg/mL) in stimulation buffer. As positive controls, 20 mL of fMLP
(chemotactic peptide N-Formyl-Met-Leu-Phe) working solution or 10 mg/
mL anti-IgE mAb (Becton Dickinson) were used. After incubation, samples
were incubated in ice for 5 minutes to stop basophil degranulation, and then
20 mL of staining reagent containing 3 mAbs (fluorescein isothiocyanate–la-
beled anti-CD63, phycoerythrin-labeled anti-CD123, and peridinin-
chlorophyll-protein complex–labeled anti–HLA-DR) was added to each
tube and incubated for 20 minutes in an ice bath covered to prevent exposure
to light. Then, 2 mL of prewarmed lysing solution to each tube was added to
lyse and fix the cells, which were incubated for 10 minutes at room tempera-
ture. Finally, after centrifuging and washing, the cells were analyzed within 2
hours in a flow cytometer by acquiring at least 500 CD1231 cells per sample.
Determination of ANAs
Both homogenous and speckled ANA patterns were detected by means of
indirect immunofluorescence with Hep-2 substrate slides (Antibodies, Inc,
Davis, Calif), according to the manufacturer’s instructions, except for thesecondary fluorescein isothiocyanate–conjugated F(ab)2 goat anti-mouse IgG
antibody (Santa Cruz Biotechnologies, Santa Cruz, Calif) at 1:20 serum as a
starting dilution. Slides were scored by an observer blinded to the experimen-
tal conditions, as previously described.E5,E6
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FIG E1. Synthetic route to compound SA-26E. III, 6-Amino-9-benzyl-2-mercapto-9H-purin-8-ol;
IVa, 4-(6-amino-9-benzyl-8-hydroxy-9H-purin-2-ylsulfanyl)-butyric acid ethyl ester; Va, 4-(6-amino-9-
benzyl-8-hydroxy-9H-purin-2-ylsulfanyl)-butyric acid; SA-26E, 4-(6-amino-9-benzyl-8-hydroxy-9H-purin-
2-ylsulfanyl)-butyric acid 2,5-dioxo-pyrrolidin-1-yl ester. The single compounds were obtained, as described
in the Methods section in this article’s Online Repository.
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FIG E2. SA-26E triggers TLR7 at high concentrations. NF-kB–dependent luciferase activity of free SA-26E–
stimulated human and mouse TLR7-expressing HEK293 cells (mean 6 SE, 5 experiments).
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TABLE E1. ANA determination in sensitized mice
Sensitization Frequency of ANA positivity (%) ANA titers
PBS 0/3 10 6 0
nDer p 2 5/6 (83) 92 6 51
nDer p 2–Conj 4/6 (66) 90 6 48
nDer p 2 1 SA-26E 3/6 (50) 42 6 24
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